PhAST Clinic: Point-of-Need AI Diagnostic Platform
PhAST has developed a phenotypic AST approach with TTR <100 min directly from urine specimens
The PhAST Clinic hardware is relatively simple, and thus affordable, while still delivering strong performance that meets or exceeds FDA requirements.
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
- Market entry
- Marketed product
- Joint Venture
- OTHER / NA
Infectious disease area:
- North America
- South America
PhAST is an AI diagnostics company developing a computer-vision platform for the rapid detection of pathogens and associated phenotypic-based AST.
The initial exemplar assay is UTIs. Preliminary work has shown that the same approach works on positive blood cultures in 100 min, faster than any other available phenotypic AST approach. Other potential assays include STIs, fungi, and yeast.